cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Zentalis Pharmaceuticals Inc
2 watching
Current Price
$23.29
$-1.23
(-5.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,327.58M
52-Week High
52-Week High
55.425
52-Week Low
52-Week Low
17.33
Average Volume
Average Volume
0.35M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,327.58M
icon52-Week High55.425
icon52-Week Low17.33
iconAverage Volume0.35M
iconDividend Yield--
iconP/E Ratio--
What does the Zentalis Pharmaceuticals Inc do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company s other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More
How much money does Zentalis Pharmaceuticals Inc make?
News & Events about Zentalis Pharmaceuticals Inc.
Business Wire
26days ago
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (Zentalis or the Company). The investigations concern whether certain of the Zentalis officers and directors breached their fiduciary duties to...
Globe Newswire
1month ago
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. The investigation concerns potential ...
Zolmax
2 months ago
Zentalis Pharmaceuticals (NASDAQ:ZNTL Get Rating) had its price target reduced by Wells Fargo & Company from $52.00 to $46.00 in a research note released on Monday, The Fly reports. A number of other research firms have also weighed in on ZNTL. HC Wainwright reduced their price objective on shares ...
Ticker Report
2 months ago
Zentalis Pharmaceuticals (NASDAQ:ZNTL Get Rating) had its price objective lowered by Wedbush from $51.00 to $32.00 in a report issued on Monday morning, The Fly reports. The firm currently has an outperform rating on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals&#8217...
Zolmax
3 months ago
Brinker Capital Investments LLC grew its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL Get Rating) by 79.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,073 shares of the companys stock after buying an ...
Frequently Asked Questions
Frequently Asked Questions
What is Zentalis Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Zentalis Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Zentalis Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Zentalis Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Zentalis Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Zentalis Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Zentalis Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Zentalis Pharmaceuticals Inc?
plus_minus_icon
What percentage is Zentalis Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Zentalis Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.29
$-1.23
(-5.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00